Lead Product(s): rQNestin34.5
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: Phase I Product Type: Large molecule
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Acquisition January 08, 2020
This acquisition solidifies Candel’s viral therapy leadership position and supports further development of Candel’s rQNestin34.5, currently in a Phase 1 study for recurrent malignant gliomas.